Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
Genetika+, a company developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases, announced today an award of up to €17.5 million of grant funding combined with equity investment to bring NeuroKaire to market. This represents the maximum possible grant from the European Commission and will be used for the company’s precision medicine tool for optimizing drug choice to treat major depressive disorder (MDD). The award was granted through the European Commission’s European Innovation Council (EIC) Accelerator for Europe’s high potential start-ups. Genetika+’s proposal was selected from over 1000 start-ups and SMEs.
“We are excited by this important vote of confidence from the European Commission’s Innovation Council,” said Talia Cohen Solal, co-founder and CEO of Genetika+. “This funding is a validation of our work to date and will accelerate our bringing this much needed tool to market, enabling providers to effectively match the right therapy to their patient's unique needs."
MDD affects 300 million people globally and can reduce an individual’s lifespan by as much as 14 years. A physician must choose from over 70 different medications and combinations when selecting a drug for a patient with MDD. Each drug takes 4 - 6 weeks to test, causing the patient to lose months to years of their lives to disability and suffering, including risk of suicide during the process of searching for the right treatment. Up to 63% of people suffering from depression do not receive adequate treatment due to the heterogeneity of the disease, uniquely affecting each individual. Response to treatment varies significantly. This trial-and-error process impacts patients’ lives, physicians time and payers and governments budgets. Precision mental health treatment is urgently needed.
The EIC funding will go toward further clinical validation of the platform, with several clinical studies underway and additional ones planned. It will also support platform scale-up to enable large scale clinical use.
Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company’s Brain-in-a-Dish technology helps physicians find the best treatment for their patients. In its first indication, depression, Genetika+ uses patented technology to rapidly test more than 70 approved antidepressants and drug combinations against an individual patient’s unique neurological biomarkers. Combined with patients’ genetic and medical history, Genetika+ can predict the optimal drug or combination therapy for each patient. This opens the door to faster treatment, fewer side effects, and lower dosing, and the elimination of arduous trial-and-error treatment protocols and needless loss of life. To learn more, follow us on LinkedIn or on Twitter @Genetikaplus.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nonprofit Funding Platform Heroe5 Launches The Good Society, Embracing Web3 Approach to the Sustainable Financial Benefit for Charities9.8.2022 19:00:00 CEST | Press release
Nonprofit funding platform Heroe5™ announced today the creation ofThe Good Society™to address the growing need for sustainable funding platforms for charitable organizations. The Good Society becomes the first project focused on Web3 solutions to raise awareness and support global causes working to positively impact our communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005376/en/ “The Good Society is a vital next step in the evolution of the fundraising industry: a Web3 platform to create art impact experiences,” said Sebastien Heimann, founding member and CEO of Heroe5 and The Good Society. “As the world moves to Web3, charities need more fundraising tools to stay ahead of the curve and embrace new ways to engage potential donors. The Good Society will provide those innovations, allowing them to raise critical funding and awareness for vital causes while feeding the public’s growing interest in digital colle
The Nature Conservancy and Global Partners Hold Session on Improving Protected Marine Areas at UN Oceans Conference With Support From Mary Kay Inc.9.8.2022 18:33:00 CEST | Press release
The United Nations Ocean Conference 2022 took place from June 27 to July 1, in Lisbon, Portugal, and brought together more than 5,000 participants, including world leaders, entrepreneurs, youth, influencers, and scientists. The conference aimed to facilitate these stakeholders in finding science-driven innovations and solutions to respond to a multidimensional ocean crisis driven by climate change, overfishing, habitat loss, and pollution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005180/en/ The Nature Conservancy logo (Logo: The Nature Conservancy) The Nature Conservancy (TNC), with support from Mary Kay Inc., held an event in collaboration with United Nations Environment Programme (UNEP), the Government of Ecuador, the Jocotoco Foundation, the Charles Darwin Foundation for the Galapagos Islands, Re:wild, and the Marine Conservation Institute. TNC and UNEP moderated the event, highlighting the critical importance
Forescout Joins CISA’s Joint Cyber Defense Collaborative9.8.2022 18:00:00 CEST | Press release
Forescout Technologies Inc., the global leader in automated cybersecurity, today announced it has joined the Joint Cyber Defense Collaborative (JCDC) to further support the U.S. government’s focus on the cybersecurity and resilience of its industrial control systems and operational technology (ICS/OT). Established by the Cybersecurity and Infrastructure Security Agency (CISA), JCDC connects cyber defenders to enable critical thinking and planning against cyberattacks. “It’s an honor to be included in the newly expanded JCDC-ICS to share Forescout’s leadership and deep expertise in ICS/OT security,” said Tim Jones, Forescout’s US Federal Government VP of Systems Engineering. “Having worked directly with CISA for years, I know this type of collaboration between industry leaders in cybersecurity is exactly what our nation needs to protect against cyberattacks that threaten critical infrastructure systems on which our daily lives depend.” Forescout’s cybersecurity solutions are used by man
Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers9.8.2022 16:50:00 CEST | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/ Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire) Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion
TNS Targets Global Growth with Strategic Acquisition of AGNITY Global9.8.2022 16:01:00 CEST | Press release
Transaction Network Services (TNS) has today announced the acquisition of AGNITY Global, a leading provider of intelligent business communication applications and infrastructure to organizations in the telecommunications and healthcare industry verticals. The move strategically enhances TNS’ Communications Market global capabilities through AGNITY’s established channel partnerships business model that spans more than 12 countries. It will also enable TNS’ existing customers to benefit from a broader portfolio of next generation solutions. Headquartered in Silicon Valley with development and support operations in Richardson, Texas and Noida, India, AGNITY powers the networks of many global Tier-1 service providers via its scalable, carrier-grade Communication Application Server (CAS). This network agnostic, multi-service software platform offers app components and open APIs that enable service providers to address network technology transition challenges as well as future-proofing their
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom